MiMedx Group Stock Price, News & Analysis (NASDAQ:MDXG)

$14.47 -0.96 (-6.22 %)
(As of 02/20/2018 10:24 AM ET)
Previous Close$14.47
Today's Range$13.88 - $15.40
52-Week Range$7.70 - $18.25
Volume3.41 million shs
Average Volume1.99 million shs
Market Capitalization$1.61 billion
P/E Ratio46.68
Dividend YieldN/A
Beta1.08

About MiMedx Group (NASDAQ:MDXG)

MiMedx Group logoMiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company's Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

Receive MDXG News and Ratings via Email

Sign-up to receive the latest news and ratings for MDXG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MDXG
CUSIPN/A
Phone770-651-9100

Debt

Debt-to-Equity RatioN/A
Current Ratio3.25%
Quick Ratio2.95%

Price-To-Earnings

Trailing P/E Ratio46.6774193548387
Forward P/E Ratio62.91
P/E Growth1.88

Sales & Book Value

Annual Sales$245.01 million
Price / Sales6.56
Cash Flow$0.18 per share
Price / Cash79.61
Book Value$1.21 per share
Price / Book11.96

Profitability

Trailing EPS$0.31
Net Income$11.97 million
Net Margins11.64%
Return on Equity17.49%
Return on Assets12.69%

Miscellaneous

Employees690
Outstanding Shares111,040,000

MiMedx Group (NASDAQ:MDXG) Frequently Asked Questions

What is MiMedx Group's stock symbol?

MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."

How will MiMedx Group's stock buyback program work?

MiMedx Group declared that its board has initiated a share repurchase plan on Wednesday, December 13th 2017, which authorizes the company to buyback $10,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to buy shares of its stock through open market purchases. Stock buyback plans are generally a sign that the company's board believes its shares are undervalued.

How were MiMedx Group's earnings last quarter?

MiMedx Group Inc (NASDAQ:MDXG) issued its quarterly earnings data on Thursday, October, 26th. The medical equipment provider reported $0.08 earnings per share for the quarter, hitting the Zacks' consensus estimate of $0.08. The medical equipment provider earned $84.60 million during the quarter, compared to the consensus estimate of $84.60 million. MiMedx Group had a return on equity of 17.49% and a net margin of 11.64%. The business's revenue was up 31.4% compared to the same quarter last year. During the same period last year, the company earned $0.06 earnings per share. View MiMedx Group's Earnings History.

Where is MiMedx Group's stock going? Where will MiMedx Group's stock price be in 2018?

4 equities research analysts have issued 1-year price targets for MiMedx Group's stock. Their forecasts range from $11.00 to $21.00. On average, they anticipate MiMedx Group's stock price to reach $17.00 in the next twelve months. View Analyst Ratings for MiMedx Group.

What are Wall Street analysts saying about MiMedx Group stock?

Here are some recent quotes from research analysts about MiMedx Group stock:

  • 1. According to Zacks Investment Research, "MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Innovations in Regenerative Biomaterials is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant. " (12/8/2017)
  • 2. Needham & Company LLC analysts commented, "MDXG announced very positive results from its Phase 2B trial of AmnioFix Injectable in plantar fasciitis and has now initiated its Phase 3 trial in support of a BLA with patient enrollment expected to begin in the next 30-60 days. Since AmnioFix Injectable is currently commercially available as a 361 HCT/P product, we expect the Phase 2B results to drive increased sales of AmnioFix Injectable on an out- of-pocket basis even before a BLA is obtained. We estimate that MDXG could complete the plantar fasciitis BLA in 2020. MDXG estimates that the US plantar fasciitis potential annual market is $450M. We also think that the plantar fasciitis trial results bode well for MDXG’s other clinical programs including: knee pain, knee osteoarthritis, and achilles tendonitis. Even with the large move MDXG shares have had recently, we do not believe that its current valuation gives it much, if any, credit for its biopharmaceutical pipeline." (8/3/2017)

Are investors shorting MiMedx Group?

MiMedx Group saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 38,958,998 shares, a decline of 6.8% from the January 12th total of 41,810,463 shares. Based on an average daily volume of 2,153,130 shares, the short-interest ratio is currently 18.1 days. Approximately 37.9% of the shares of the stock are sold short.

Who are some of MiMedx Group's key competitors?

Who are MiMedx Group's key executives?

MiMedx Group's management team includes the folowing people:

  • Parker H. Petit Jr., Chairman of the Board, Chief Executive Officer (Age 77)
  • William Charles Taylor, President, Chief Operating Officer, Director (Age 48)
  • Michael J. Senken, Chief Financial Officer (Age 58)
  • Alexandra O. Haden, General Counsel, Secretary (Age 42)
  • Charles E. Koob, Director (Age 72)
  • Luis A. Aguilar, Independent Director (Age 63)
  • Joseph G. Bleser, Independent Director (Age 71)
  • J. Terry Dewberry, Independent Director (Age 73)
  • Charles R. Evans, Independent Director (Age 70)

Who owns MiMedx Group stock?

MiMedx Group's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.25%), Consonance Capital Management LP (5.40%), Millennium Management LLC (1.98%), The Manufacturers Life Insurance Company (1.27%), Bank of New York Mellon Corp (1.21%) and Geode Capital Management LLC (0.84%). Company insiders that own MiMedx Group stock include Parker H Petit and William Charles Taylor. View Institutional Ownership Trends for MiMedx Group.

Who sold MiMedx Group stock? Who is selling MiMedx Group stock?

MiMedx Group's stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., HBK Investments L P, Two Sigma Advisers LP, Deutsche Bank AG, Two Sigma Investments LP, Old Mutual Global Investors UK Ltd., Mckinley Capital Management LLC Delaware and Geode Capital Management LLC. View Insider Buying and Selling for MiMedx Group.

Who bought MiMedx Group stock? Who is buying MiMedx Group stock?

MiMedx Group's stock was purchased by a variety of institutional investors in the last quarter, including Consonance Capital Management LP, The Manufacturers Life Insurance Company , Senzar Asset Management LLC, Think Investments LP, Allianz Asset Management GmbH, Arrowstreet Capital Limited Partnership, Thrivent Financial For Lutherans and Millennium Management LLC. View Insider Buying and Selling for MiMedx Group.

How do I buy MiMedx Group stock?

Shares of MiMedx Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MiMedx Group's stock price today?

One share of MiMedx Group stock can currently be purchased for approximately $14.47.

How big of a company is MiMedx Group?

MiMedx Group has a market capitalization of $1.61 billion and generates $245.01 million in revenue each year. The medical equipment provider earns $11.97 million in net income (profit) each year or $0.31 on an earnings per share basis. MiMedx Group employs 690 workers across the globe.

How can I contact MiMedx Group?

MiMedx Group's mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The medical equipment provider can be reached via phone at 770-651-9100 or via email at [email protected]


MarketBeat Community Rating for MiMedx Group (MDXG)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  282 (Vote Outperform)
Underperform Votes:  148 (Vote Underperform)
Total Votes:  430
MarketBeat's community ratings are surveys of what our community members think about MiMedx Group and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MiMedx Group (NASDAQ:MDXG) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.60
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.00$17.00$17.00$15.80
Price Target Upside: 41.78% upside41.78% upside42.50% upside4.36% downside

MiMedx Group (NASDAQ:MDXG) Consensus Price Target History

Price Target History for MiMedx Group (NASDAQ:MDXG)

MiMedx Group (NASDAQ:MDXG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/14/2017Lake Street CapitalSet Price TargetBuy$18.00LowView Rating Details
12/1/2017Piper Jaffray CompaniesReiterated RatingBuy$18.00LowView Rating Details
12/1/2017Needham & Company LLCReiterated RatingBuy$21.00LowView Rating Details
5/23/2017First AnalysisDowngradeEqual Weight -> Underweight$11.00HighView Rating Details
11/7/2016AegisInitiated CoverageBuy$12.00N/AView Rating Details
6/29/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

MiMedx Group (NASDAQ:MDXG) Earnings History and Estimates Chart

Earnings by Quarter for MiMedx Group (NASDAQ:MDXG)

MiMedx Group (NASDAQ MDXG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/26/2017Q3 2017$0.08$0.08$84.60 million$84.60 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.07$0.07$74.22 million$76.40 millionViewN/AView Earnings Details
4/28/2017Q1 2017$0.07$0.07$72.60 million$72.60 millionViewN/AView Earnings Details
2/23/2017Q416$0.08$0.05$71.13 million$69.90 millionViewListenView Earnings Details
10/27/2016Q316$0.06$0.06$63.18 million$64.40 millionViewListenView Earnings Details
7/26/2016Q216$0.07$0.05$56.49 million$57.00 millionViewListenView Earnings Details
4/25/2016Q116$0.05$0.04$54.05 million$53.40 millionViewListenView Earnings Details
2/23/2016Q415$0.06$0.12$51.84 million$51.80 millionViewListenView Earnings Details
10/29/2015Q315$0.06$0.06$48.61 million$49.00 millionViewListenView Earnings Details
7/30/2015Q215$0.04$0.05$45.03 million$45.68 millionViewListenView Earnings Details
4/27/2015Q1$0.03$0.04$40.77 millionViewListenView Earnings Details
2/26/2015Q414$0.03$0.03$38.15 million$39.60 millionViewListenView Earnings Details
10/30/2014Q314$0.02$0.03$33.50 million$33.50 millionViewListenView Earnings Details
4/25/2014Q114($0.02)($0.01)$19.09 million$19.60 millionViewListenView Earnings Details
2/26/2014Q4($0.01)($0.04)$18.31 million$18.00 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.01)($0.01)$12.94 million$13.52 millionViewListenView Earnings Details
5/1/2013Q1 2013($0.02)($0.02)$11.34 million$11.56 millionViewListenView Earnings Details
3/7/2013Q4 2012($0.01)($0.01)ViewN/AView Earnings Details
10/29/2012Q3 2012($0.05)ViewN/AView Earnings Details
5/2/2012Q1 2012($0.02)ViewN/AView Earnings Details
2/28/2012Q4 2011($0.25)ViewN/AView Earnings Details
10/26/2011Q3 2011($0.02)ViewN/AView Earnings Details
7/25/2011Q2 2011($0.03)ViewN/AView Earnings Details
4/26/2011Q1 2011($0.05)ViewN/AView Earnings Details
3/28/2011Q4 2010($0.04)ViewN/AView Earnings Details
10/26/2010Q3 2010($0.05)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

MiMedx Group (NASDAQ:MDXG) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.06$0.06$0.06
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for MiMedx Group (NASDAQ:MDXG)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

MiMedx Group (NASDAQ MDXG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.40%
Institutional Ownership Percentage: 71.15%
Insider Trades by Quarter for MiMedx Group (NASDAQ:MDXG)
Institutional Ownership by Quarter for MiMedx Group (NASDAQ:MDXG)

MiMedx Group (NASDAQ MDXG) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/14/2017William Charles TaylorInsiderSell80,000$14.52$1,161,600.00547,424View SEC Filing  
5/25/2017William Charles TaylorInsiderSell26,571$13.74$365,085.54533,612View SEC Filing  
4/27/2017William Charles TaylorInsiderSell26,000$11.40$296,400.00540,460View SEC Filing  
9/6/2016William Charles TaylorInsiderSell20,400$7.55$154,020.00566,566View SEC Filing  
8/1/2016William Charles TaylorInsiderSell29,112$7.55$219,795.60612,316View SEC Filing  
6/16/2016William Charles TaylorCOOSell24,333$7.52$182,984.16616,078View SEC Filing  
5/20/2016Parker H PetitCEOBuy20,000$6.99$139,800.005,009,121View SEC Filing  
5/17/2016Parker H PetitCEOBuy30,000$6.82$204,600.004,989,121View SEC Filing  
5/13/2016Parker H PetitCEOBuy40,000$6.75$270,000.004,959,121View SEC Filing  
5/12/2016Parker H PetitCEOBuy50,000$6.74$337,000.004,919,121View SEC Filing  
11/13/2015Charles Robert EvansDirectorBuy10,000$7.84$78,400.0031,878View SEC Filing  
11/10/2015Parker H PetitCEOBuy131,925$7.58$999,991.505,026,821View SEC Filing  
10/30/2015Alexandra O. HadenGeneral CounselBuy4,150$7.92$32,868.0040,528View SEC Filing  
5/28/2015Larry W PapasanDirectorSell5,958$10.09$60,116.22View SEC Filing  
5/18/2015William Charles TaylorCOOSell150,000$10.01$1,501,500.00View SEC Filing  
10/31/2014William Charles TaylorCOOSell150,000$10.01$1,501,500.00View SEC Filing  
7/1/2014William Charles TaylorCOOSell150,000$7.50$1,125,000.00View SEC Filing  
1/17/2014Parker PetitCEOSell150,000$8.28$1,242,000.00View SEC Filing  
8/28/2013William Charles TaylorCOOSell9,800$6.15$60,270.00View SEC Filing  
8/7/2013William Charles TaylorCOOSell183,765$6.21$1,141,180.65View SEC Filing  
5/16/2013Steve GorlinDirectorSell30,000$6.46$193,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MiMedx Group (NASDAQ MDXG) News Headlines

Source:
DateHeadline
Block & Leviton LLP Investigates MiMedx Group, Inc. (MDXG) Following Internal Investigation Over Accounting PracticesBlock & Leviton LLP Investigates MiMedx Group, Inc. (MDXG) Following Internal Investigation Over Accounting Practices
www.prnewswire.com - February 20 at 9:49 AM
Zacks: Brokerages Expect MiMedx Group Inc (MDXG) to Post $0.10 EPSZacks: Brokerages Expect MiMedx Group Inc (MDXG) to Post $0.10 EPS
www.americanbankingnews.com - February 18 at 5:12 PM
Contrasting MiMedx Group (MDXG) and Steris (STE)Contrasting MiMedx Group (MDXG) and Steris (STE)
www.americanbankingnews.com - February 17 at 12:26 PM
MDXG Makes Notable Cross Below Critical Moving AverageMDXG Makes Notable Cross Below Critical Moving Average
www.nasdaq.com - February 17 at 8:26 AM
MiMedx: Latest Short Seller Accusation Unsubstantiated, Intended To Manipulate Stock PriceMiMedx: Latest Short Seller Accusation 'Unsubstantiated,' Intended To Manipulate Stock Price
www.benzinga.com - February 17 at 8:26 AM
This Short Seller Pressed ‘Tweet.’ Then the FBI Showed UpThis Short Seller Pressed ‘Tweet.’ Then the FBI Showed Up
finance.yahoo.com - February 16 at 8:31 AM
XBI, BIVV, JUNO, MDXG: Large Inflows Detected at ETF - Nasdaq.com - NasdaqXBI, BIVV, JUNO, MDXG: Large Inflows Detected at ETF - Nasdaq.com - Nasdaq
www.nasdaq.com - February 15 at 8:04 AM
MiMedx Group Inc (MDXG) Short Interest Down 6.8% in JanuaryMiMedx Group Inc (MDXG) Short Interest Down 6.8% in January
www.americanbankingnews.com - February 10 at 2:24 AM
A Deep Look at Globus Medical’s Financial PerformanceA Deep Look at Globus Medical’s Financial Performance
finance.yahoo.com - February 8 at 8:22 AM
MiMedx Group Inc (MDXG) Receives Consensus Rating of "Hold" from BrokeragesMiMedx Group Inc (MDXG) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 2 at 11:16 AM
MiMedx Group (MDXG) Upgraded to "Buy" at BidaskClubMiMedx Group (MDXG) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - January 31 at 10:54 PM
MiMedx Group Inc (MDXG) Short Interest Down 0.1% in JanuaryMiMedx Group Inc (MDXG) Short Interest Down 0.1% in January
www.americanbankingnews.com - January 30 at 2:46 PM
Noteworthy Friday Option Activity: MDXG, URI, SWKSNoteworthy Friday Option Activity: MDXG, URI, SWKS
www.nasdaq.com - January 27 at 10:06 AM
MiMedx Group (MDXG) Provides Commentary on Magistrate Recommendation in Lawsuit Against Short Sellers; Recommendations are in ErrorMiMedx Group (MDXG) Provides Commentary on Magistrate Recommendation in Lawsuit Against Short Sellers; 'Recommendations are in Error'
www.streetinsider.com - January 19 at 10:54 AM
MiMedx Comments on Magistrate Recommendation in the Companys Lawsuit Against Short SellersMiMedx Comments on Magistrate Recommendation in the Company's Lawsuit Against Short Sellers
finance.yahoo.com - January 18 at 10:41 AM
MiMedx Group (MDXG) Reports First Patient Enrollment in Phase 3 Clinical Trial of AmnioFix Injectable for Achilles TendonitisMiMedx Group (MDXG) Reports First Patient Enrollment in Phase 3 Clinical Trial of AmnioFix Injectable for Achilles Tendonitis
www.streetinsider.com - January 17 at 5:13 PM
MiMedx Announces the Enrollment of the First Patients in the Phase 3 Clinical Trial of AmnioFix® Injectable for Achilles TendonitisMiMedx Announces the Enrollment of the First Patients in the Phase 3 Clinical Trial of AmnioFix® Injectable for Achilles Tendonitis
finance.yahoo.com - January 17 at 9:38 AM
MiMedx Announces First Patients Have Been Enrolled In The Phase 3 Clinical Trial Of AmnioFix® Injectable In Patients With Recalcitrant Plantar Fasciitis PainMiMedx Announces First Patients Have Been Enrolled In The Phase 3 Clinical Trial Of AmnioFix® Injectable In Patients With Recalcitrant Plantar Fasciitis Pain
finance.yahoo.com - January 16 at 9:47 AM
MiMedx Group Inc (MDXG) Expected to Announce Earnings of $0.10 Per ShareMiMedx Group Inc (MDXG) Expected to Announce Earnings of $0.10 Per Share
www.americanbankingnews.com - January 15 at 7:14 PM
Mimedx To Host Shareholder Call On January 18,...Mimedx To Host Shareholder Call On January 18,...
www.benzinga.com - January 13 at 9:42 AM
Mimedx To Host Shareholder Call On January 18, 2018 To Update Progress On Multiple Clinical Studies And Status Of Patent PortfolioMimedx To Host Shareholder Call On January 18, 2018 To Update Progress On Multiple Clinical Studies And Status Of Patent Portfolio
finance.yahoo.com - January 13 at 9:42 AM
MiMedx Obtains Successful Settlement Of Its Patent Infringement Lawsuit Against Musculoskeletal Transplant Foundation, Medline Industries And Liventa Bioscience, Inc.MiMedx Obtains Successful Settlement Of Its Patent Infringement Lawsuit Against Musculoskeletal Transplant Foundation, Medline Industries And Liventa Bioscience, Inc.
finance.yahoo.com - January 11 at 5:12 PM
MiMedx Joins Elite Club Of Stocks With RS Ratings Over 90MiMedx Joins Elite Club Of Stocks With RS Ratings Over 90
finance.yahoo.com - January 10 at 5:04 PM
MiMedx Shows Market Leadership With Jump To 84 RS RatingMiMedx Shows Market Leadership With Jump To 84 RS Rating
finance.yahoo.com - January 9 at 5:11 PM
MiMedx Group Inc (MDXG) Receives Average Recommendation of "Hold" from BrokeragesMiMedx Group Inc (MDXG) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 8 at 9:40 AM
MiMedx Releases Preliminary 2017 Revenue of $324.5 Million representing a 32% increase over 2016MiMedx Releases Preliminary 2017 Revenue of $324.5 Million representing a 32% increase over 2016
www.prnewswire.com - January 7 at 2:10 PM
MiMedx Provides Update On Illegal Short Selling Activities Against The CompanyMiMedx Provides Update On Illegal Short Selling Activities Against The Company
www.bizjournals.com - January 6 at 9:45 AM
BidaskClub Downgrades MiMedx Group (MDXG) to SellBidaskClub Downgrades MiMedx Group (MDXG) to Sell
www.americanbankingnews.com - January 6 at 12:48 AM
MiMedx: Unique Opportunity Provided By Aggressive Shorts - Seeking AlphaMiMedx: Unique Opportunity Provided By Aggressive Shorts - Seeking Alpha
seekingalpha.com - January 2 at 11:16 PM
MiMedx To Present At 36th Annual JP Morgan Healthcare Conference - PR Newswire (press release)MiMedx To Present At 36th Annual JP Morgan Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - January 2 at 6:13 PM
MiMedx To Present At 36th Annual J.P. Morgan Healthcare ConferenceMiMedx To Present At 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 6:13 PM
MiMedx Group (MDXG) Issues New Response to Short Sellers - StreetInsider.comMiMedx Group (MDXG) Issues New Response to Short Sellers - StreetInsider.com
www.streetinsider.com - December 29 at 10:17 AM
MiMedx Group (MDXG) Stock Rating Upgraded by BidaskClubMiMedx Group (MDXG) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - December 27 at 7:26 PM
MiMedx Group (MDXG) Settles Lawsuit with Former Employee - StreetInsider.comMiMedx Group (MDXG) Settles Lawsuit with Former Employee - StreetInsider.com
www.streetinsider.com - December 20 at 9:47 AM
MiMedx Agrees To Lawsuit Settlement With Former EmployeeMiMedx Agrees To Lawsuit Settlement With Former Employee
finance.yahoo.com - December 19 at 9:47 AM
Does MiMedx Group Inc’s (NASDAQ:MDXG) Past Performance Indicate A Stronger Future?Does MiMedx Group Inc’s (NASDAQ:MDXG) Past Performance Indicate A Stronger Future?
finance.yahoo.com - December 16 at 5:02 PM
Notable Friday Option Activity: V, MDXG, DISCKNotable Friday Option Activity: V, MDXG, DISCK
www.nasdaq.com - December 15 at 5:38 PM
ETFs with exposure to MiMedx Group, Inc. : December 14, 2017ETFs with exposure to MiMedx Group, Inc. : December 14, 2017
finance.yahoo.com - December 14 at 5:38 PM
MiMedx Group, Inc. – Value Analysis (NASDAQ:MDXG) : December 14, 2017MiMedx Group, Inc. – Value Analysis (NASDAQ:MDXG) : December 14, 2017
finance.yahoo.com - December 14 at 5:38 PM
MiMedx Group (MDXG) Given a $18.00 Price Target at Lake Street CapitalMiMedx Group (MDXG) Given a $18.00 Price Target at Lake Street Capital
www.americanbankingnews.com - December 14 at 4:12 PM
MiMedx Group (MDXG) Offers FY18 Guidance - StreetInsider.com - StreetInsider.comMiMedx Group (MDXG) Offers FY18 Guidance - StreetInsider.com - StreetInsider.com
www.streetinsider.com - December 13 at 5:15 PM
Stock Repurchase Plan Announced by MiMedx Group (MDXG) Board Stock Repurchase Plan Announced by MiMedx Group (MDXG) Board
www.americanbankingnews.com - December 13 at 11:10 AM
MiMedx Group, Inc. breached its 50 day moving average in a Bullish Manner : MDXG-US : December 13, 2017MiMedx Group, Inc. breached its 50 day moving average in a Bullish Manner : MDXG-US : December 13, 2017
finance.yahoo.com - December 13 at 10:04 AM
MiMedx Forecasts 2018 Revenue To Be In The Range Of $383 Million To $387 MillionMiMedx Forecasts 2018 Revenue To Be In The Range Of $383 Million To $387 Million
finance.yahoo.com - December 13 at 10:04 AM
MiMedx Group Inc (MDXG) Short Interest UpdateMiMedx Group Inc (MDXG) Short Interest Update
www.americanbankingnews.com - December 13 at 1:10 AM
MiMedx Announces Release Of 2018 Guidance And Shareholder Conference CallMiMedx Announces Release Of 2018 Guidance And Shareholder Conference Call
finance.yahoo.com - December 12 at 5:31 PM
MiMedx Group (MDXG) Lowered to "Sell" at Zacks Investment ResearchMiMedx Group (MDXG) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - December 8 at 11:50 PM
Two Independent Poster Abstracts Highlighting The Clinical Efficacy of MiMedx Allografts are Recognized at The 2017 Desert Foot ConferenceTwo Independent Poster Abstracts Highlighting The Clinical Efficacy of MiMedx Allografts are Recognized at The 2017 Desert Foot Conference
finance.yahoo.com - December 6 at 5:08 PM
MiMedx Group (MDXG) and Sientra (SIEN) Financial ReviewMiMedx Group (MDXG) and Sientra (SIEN) Financial Review
www.americanbankingnews.com - December 4 at 3:18 PM
MiMedx Group (MDXG) Sees Exceeding Top End of Q4 Revenue GuidanceMiMedx Group (MDXG) Sees Exceeding Top End of Q4 Revenue Guidance
www.streetinsider.com - December 1 at 5:04 PM

SEC Filings

MiMedx Group (NASDAQ:MDXG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

MiMedx Group (NASDAQ:MDXG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MiMedx Group (NASDAQ MDXG) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.